VanEck Associates’s Axsome Therapeutics AXSM Stock Holding History

VanEck Associates’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.17M	Sell	29,309 -8,364	-22%	-$1.81M	﹤0.01%	735
2026 Q1	$6.37M	Buy	37,673 +2,596	+7%	+$448K	﹤0.01%	739
2025 Q4	$6.41M	Buy	35,077 +20,204	+136%	+$2.82M	0.01%	711
2025 Q3	$1.81M	Sell	14,873 -1,460	-9%	-$164K	﹤0.01%	999
2025 Q2	$1.71M	Sell	16,333 -46,662	-74%	-$4.94M	﹤0.01%	971
2025 Q1	$7.35M	Buy	+62,995	New	+$7.18M	0.01%	571

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VanEck Associates's AXSM Position: Q2 2026 in Review

VanEck Associates reduced its Axsome Therapeutics (AXSM) stake by 22% in Q2 2026, selling an estimated $1.81M and leaving 29,309 shares worth $7.17M. The position accounts for ﹤0.01% of the portfolio, ranked #735.

VanEck Associates first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.35M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

VanEck Associates held 29,309 shares of Axsome Therapeutics worth $7.17M as of Q2 2026.
VanEck Associates sold 8,364 Axsome Therapeutics shares in Q2 2026, an estimated $1.81M.
Axsome Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #735 holding.
VanEck Associates first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
VanEck Associates's Axsome Therapeutics position peaked at $7.35M in Q1 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.